In plain English
Cullinan Therapeutics Inc develops biologic medicines and related therapies, focusing on cancer treatments. The company’s zipalertinib…
Company stock · NASDAQ NMS - GLOBAL MARKET · USD
CGEM
Cullinan Therapeutics Inc
—
Price unavailable — company details still show below
- Industry
- Biotechnology
- Market value
- $924.8 million
- Number of shares
- 64.3 million
- Country
- US
- Went public
- Jan 8, 2021
- Exchange
- NASDAQ NMS - GLOBAL MARKET
- Website
- cullinantherapeutics.com
Price chart Pro
Loading chart…
Loading chart…
Company briefing
What CGEM is
Plain English context — why the name shows up in the news, and what to watch next.
Latest on this name
Insights & deeper context
1 recent card — open any for the full deeper dive.
Cullinan Therapeutics Zipalertinib Combo Clears Key Phase 3 Hurdle As First-Line Lung Cancer Treatment Option Takes Shape
In brief
Cullinan Therapeutics' zipalertinib combo cleared a key Phase 3 hurdle, showing strong efficacy and tolerability in a first-line lung cancer treatment option.
Company reports
Official filings (US SEC and linked cards)
No filings here yet
Official report cards for CGEM will show up here when available.
Broad market indexes (like the S&P 500, a basket of 500 large US companies) are shown through popular funds that track them (for example SPY). Company profile and prices use live market data when available.